Form 4 for LLY Lilly (Eli)
Accepted 2023-02-14 00:00:00 ET · period of report 2023-02-10 · accession 0000059478-23-000069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-14 | 2023-02-10+ | LLY | White Anne E. | EVP, Pres, Lilly Neuroscience | S - Sale | $344.62 | -5,000 | 57.9K | -8% | -$1.72M |
| D | 2023-02-14 | 2023-02-10 | LLY | White Anne E. | EVP, Pres, Lilly Neuroscience | A - Grant | $345.12 | +8,562 | 62.9K | +16% | +$2.95M |
| D | 2023-02-14 | 2023-02-10 | LLY | White Anne E. | EVP, Pres, Lilly Neuroscience | A - Grant | $0.00 | +4,124 | 4,124 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-10 | S | D | 2,500 | $342.76 | 60,426 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-10 | A | A | 8,562 | $345.12 | 62,926 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-13 | S | D | 2,500 | $346.47 | 57,926 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2023-02-10 | A | A | 4,124 | $0.00 | 4,124 | D | — · 2024-02-01 to 2024-02-01 | 4,124 Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |